Nebivolol과 다른 베타차단제가 발기부전에 끼치는 영향 비교: 체계적 문헌 고찰 및 메타분석
The Impact of Nebivolol versus Other Beta-blockers on Erectile Dysfunction: Systematic Review and Meta-Analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The occurrence of erectile dysfunction (ED) due to anti-hypertensive drugs has been frequently reported, and many studies suggested the causality of β-blockers in increasing the ED risk. However, unlike other β-blockers, nebivolol is known to reduce the risk of ED occurrence or to improve erectile function. In this study, we conducted a systematic review and meta-analysis to compare the ED incidence between nebivolol and other β-blockers. Methods: The search for literature was conducted on May 19−21, 2020 through PubMed, Embase, and Cochrane. Using a random- effects model, the odds ratio for the occurrence of ED was computed for studies included for meta-analysis. The mean difference of the International Index of Erectile Function (IIEF) scores before and after drug treatments was also compared between patients treated with Nebivolol and with other β-blockers. Results: The probability of ED occurrence in the nebivolol group was 0.69 times higher than that in other β-blockers group [95% confidence interval (CI): 0.31−1.53, heterogeneity: I2=0%]. In addition, the post-drug IIEF scores of the nebivolol group were 1.07 points less reduced than that of other β-blockers groups (95% CI: 0.69−1.45, heterogeneity: I2=0%). Conclusion: Our results showed that the IIEF score had a smaller drop in nebivolol group than that in other β-blockers groups. Although the difference of ED incidence between two groups was not significant, all studies showed same results that the ED incidence is lower in nebivolol group than in other β-blockers group. Thus, we confirm that, unlike other β-blockers, nebivolol has a clinical effect that protects the sexual function of men.
Abstract
Objectives: The occurrence of erectile dysfunction (ED) due to anti-hypertensive drugs has been frequently reported, and many studies suggested the causality of β-blockers in increasing the ED risk. However, unlike other β-blockers, nebivolol is known to reduce the risk of ED occurrence or to improve erectile function. In this study, we conducted a systematic review and meta-analysis to compare the ED incidence between nebivolol and other β-blockers. Methods: The search for literature was conducted on May 19−21, 2020 through PubMed, Embase, and Cochrane. Using a random- effects model, the odds ratio for the occurrence of ED was computed for studies included for meta-analysis. The mean difference of the International Index of Erectile Function (IIEF) scores before and after drug treatments was also compared between patients treated with Nebivolol and with other β-blockers. Results: The probability of ED occurrence in the nebivolol group was 0.69 times higher than that in other β-blockers group [95% confidence interval (CI): 0.31−1.53, heterogeneity: I2=0%]. In addition, the post-drug IIEF scores of the nebivolol group were 1.07 points less reduced than that of other β-blockers groups (95% CI: 0.69−1.45, heterogeneity: I2=0%). Conclusion: Our results showed that the IIEF score had a smaller drop in nebivolol group than that in other β-blockers groups. Although the difference of ED incidence between two groups was not significant, all studies showed same results that the ED incidence is lower in nebivolol group than in other β-blockers group. Thus, we confirm that, unlike other β-blockers, nebivolol has a clinical effect that protects the sexual function of men.
참고문헌 (13)
- "snuh.org"[URL]
- 서준상, "한국 남성의 비만과 전립선 비대증, 발기부전과의 연관성", Journal of Urologic Oncology, 13(3), pp.122~127 (2015), 대한비뇨기종양학회
- Doumas M, "Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients", Asian J Androl, 8, pp.177~182 (2006)
- Botros SM, "Effect of different beta blockers on penile vascular velocities in hypertensive males", Egypt J Radiol Nucl Med, 46, pp.749~754 (2015)
- Brixius K, "Nitric oxide, erectile dysfunction and beta-blocker treatment(MR NOED study) : benefit of nebivolol versus metoprolol in hypertensive men", Clin Exp Pharmacol Physiol, 34, pp.327~331 (2007)
- Sharp RP, "Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction", Therapeutic advances in urology, 9, pp.59~63 (2017)
- "training.cochrane.org"[URL]
- NECA’s guidance for undertaking systematic reviews and meta-analyses for intervention, "Kim SY", National Evidence-based healthcare Collaborating Agency, 1~287 (2011)
- Aldemir M, "Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft", Anatol J Cardiol, 16, pp.131~136 (2016)
- Espinola-Klein C, "β-Blockers in patients with intermittent claudication and arterial hypertension : results from the nebivolol or metoprolol in arterial occlusive disease trial", Hypertension, 58, pp.148~154 (2011)
- Grassi G, "Efficacy and tolerability profile of nebivolol vs atenolol in mild-tomoderate essential hypertension : results of a double-blind randomized multicentre trial", Blood Press Suppl, 2, pp.35~40 (2003)
- Gür Ö, "The comparison of the effects of nebivolol and metoprolol on erectile dysfunction in the cases with coronary artery bypass surgery", Ann Thorac Cardiovasc Surg, 23, pp.91~95 (2017)
- George M, "Effect of nebivolol on endothelial dysfunction in coronary artery disease patients-an open label randomized controlled clinical trial(NEDCAD)", J Cardiovasc Disease Res, 8, pp.42~45 (2017)